ACRS - Aclaris Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ACRS is currently covered by 6 analysts with an average price target of $9.1. This is a potential upside of $7.4 (435.29%) from yesterday's end of day stock price of $1.7.

Aclaris Therapeutics's activity chart (see below) currently has 42 price targets and 56 ratings on display. The stock rating distribution of ACRS is 56.52% BUY and 43.48% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 28.79% with an average time for these price targets to be met of 160.45 days.

Highest price target for ACRS is $16, Lowest price target is $6, average price target is $7.83.

Most recent stock forecast was given by CHRISTOPHER RAYMOND from PIPER SANDLER on 10-Jul-2025. First documented stock forecast 02-Nov-2015.

Currently out of the existing stock ratings of ACRS, 13 are a BUY (56.52%), 10 are a HOLD (43.48%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$6

$4.39 (272.67%)

$13

15 days ago
(10-Jul-2025)

1/6 (16.67%)

$4.41 (277.36%)

354

Buy

$16

$14.39 (893.79%)

$16

1 months ago
(25-Jun-2025)

0/7 (0%)

$14.37 (881.60%)

Buy

$9

$7.39 (459.01%)

2 months 16 days ago
(09-May-2025)

0/8 (0%)

$7.74 (614.29%)

Buy

$8

$6.39 (396.89%)

8 months 6 days ago
(19-Nov-2024)

0/3 (0%)

$3.41 (74.29%)

Buy

$7

$5.39 (334.78%)

8 months 6 days ago
(19-Nov-2024)

1/4 (25%)

$2.41 (52.51%)

315

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ACRS (Aclaris Therapeutics) average time for price targets to be met?

On average it took 160.45 days on average for the stock forecasts to be realized with a an average price target met ratio 28.79

Which analyst has the current highest performing score on ACRS (Aclaris Therapeutics) with a proven track record?

DAVID STEINBERG

Which analyst has the most public recommendations on ACRS (Aclaris Therapeutics)?

David Steinberg has 2 price targets and 2 ratings on ACRS

Which analyst is the currently most bullish on ACRS (Aclaris Therapeutics)?

Corinne Jenkins with highest potential upside - $19.39

Which analyst is the currently most reserved on ACRS (Aclaris Therapeutics)?

Alex Thompson with lowest potential downside - -$0.61

Aclaris Therapeutics in the News

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright...

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

– Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 – – Expected Cash Runway Extended Through the First Half of 2028 – – Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships – – Investigational New Drug (IND)...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?